Navigation Links
Aware, Inc. Reports Second Quarter 2013 Financial Results
Date:7/23/2013

BEDFORD, Mass., July 23, 2013 /PRNewswire/ -- Aware, Inc. (NASDAQ: AWRE), a leading supplier of biometrics software and services and DSL service assurance software products, today reported financial results for its second quarter ended June 30, 2013. 

Revenue for the second quarter of 2013 was $4.9 million, an increase of 19% compared to $4.1 million in the same quarter last year. Net income for the second quarter of 2013 was $307,000, or $0.01 per diluted share, which compares to net income of $54.9 million, or $2.49 per diluted share, for the same period a year ago. Net income in the second quarter of 2012 included a gain on the sale of patent assets of $71.2 million.  Operating income before patent related income in the second quarter of 2013 was $283,000 compared to $119,000 in the second quarter of 2012.

For the six months ended June 30, 2013, revenue increased 17% to $10.5 million, compared to $9.0 million in the same period a year ago.  Net income for the six months ended June 30, 2013 was $2.2 million, or $0.10 per diluted share. These results compared to net income of $56.0 million, or $2.60 per diluted share, for the same period a year ago. Year-to-date net income in 2012 also included the aforementioned $71.2 million gain on the sale of patent assets.  Operating income before patent related income for the first six months of 2013 was $2.3 million compared to $1.2 million for the same period a year ago.

The improvement in operating income before patent related income in the three and six month periods this year compared to the corresponding periods last year was primarily due to increased profitability in our biometrics business and lower general and administrative expenses.

Rick Moberg, Aware's co-chief executive officer and chief financial officer, said, "We are pleased to report this is our eight consecutive profitable qu
'/>"/>

SOURCE Aware, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology news :

1. Aware, Inc. Reports First Quarter 2012 Financial Results
2. Aware, Inc. Reports Second Quarter 2012 Financial Results
3. Aware, Inc. Reports Third Quarter 2012 Financial Results
4. Aware, Inc. Declares Special Cash Dividend of $1.80 Per Share, or Approximately $40 Million in Total
5. NASDAQ Sets Ex-Dividend Date for Aware, Inc.s Special Cash Dividend of $1.80 Per Share
6. Aware, Inc. Reports First Quarter 2013 Financial Results
7. Radiologists study necessity of additional imaging recommendations in PET/CT oncologic reports
8. BGI reports the completed sequence of foxtail millet genome
9. GEN reports on growth of tissue engineering revenues
10. BGI reports the latest finding on NMNAT1 mutations linked to Leber congenital amaurosis
11. GEN reports on recent progress in Alzheimers research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2015)... , Jul. 13, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... provisional patent 62/188684 for BEHAVIORAL-DIRECTED AUTHENTIATION ... new convenient and secure method to make payments.  ... payment methods, introduced with its groundbreaking voice-direct payment ...
(Date:7/8/2015)... 2015 Summary Pancreatic cancer is the ... fatal, with a mortality rate of 10.9 deaths per ... cancer patients has highlighted a significant need for new ... met by the current market. A highly active ... varying molecule types and mechanisms of action, which provides ...
(Date:7/7/2015)... , July 7, 2015  Based on ... Frost & Sullivan recognizes Credence ID, LLC with ... Entrepreneurial Company of the Year Award. Credence ID ... aid in its mission of offering enrollment and ... globally. As Credence ID was formed by experts ...
Breaking Biology News(10 mins):NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5
... weekend warriors: the simple act of exercise and not ... a new University of Florida study finds. People ... gaining strength or boosting cardiovascular fitness feel just as ... said Heather Hausenblas, a UF exercise psychologist. Her study ...
... sees the launch of Ensembl Plants a ... by the European Molecular Biology Laboratory,s European ... Spring Harbor Laboratory, USA. Ensembl Plants allows researchers ... genome-scale experiments in different plant species. By pinpointing ...
... disease and other diet related health problems received a 4 ... projects. The projects, taking place in universities and research institutes ... publicly-funded Research Councils and 15 companies. This means the research ... in our society but in a way that the food ...
Cached Biology News:UF study: Exercise improves body image for fit and unfit alike 2UF study: Exercise improves body image for fit and unfit alike 3New portal for plant genomics will support research into improved crops 2Public sector and industry unite to attack obesity and heart disease 2
(Date:7/29/2015)... ... July 29, 2015 , ... ... supplier, announces the launch of their 2nd generation cell therapy POD® design. The ... CT, but it also represents a new POD® design. , “G-CON first ...
(Date:7/29/2015)... 2015  AmnioChor Inc., an early stage biotech startup ... to announce that the Musculoskeletal Transplant Foundation of ... in their seed round of development of the proprietary ... AmnioChor,s technology allows cryopreservation of the ... cells living within those tissues. Amnion is a well-established ...
(Date:7/29/2015)... 2015  Indivior PLC (LON: INDV) today announced that ... was accepted and received Priority Review by the U.S. ... opioid overdose. This naloxone nasal spray comes as a ... absorption into the nasal mucosa. 1 The device ... may be better equipped to help an opioid overdose ...
(Date:7/29/2015)... QUEBEC CITY , July 29, 2015 /PRNewswire/ ... (the "Company") today announced it has selected an optimized ... important milestone in the development of a new ... The MAPK pathway represents a prime target for ... significant antitumor activities and survival benefits for B-Raf ...
Breaking Biology Technology:G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3
... N.J., June 23 SyntheMed, Inc. (OTC Bulletin Board: ... commercialization of anti-adhesion products, announced today that the company ... Health Innovation Award in pediatrics. The company ... & Sullivan medical device analysts in recognition of the ...
... CHICAGO, June 23 Advanced Life Sciences Holdings, Inc. ... non-human primate study involving its novel, once-a-day, oral antibiotic ... achieved a 100% survival rate against an inhaled lethal ... study that received 16 mg/kg once-a-day (the human equivalent ...
... to Double 2009 Grant Awards to Nearly $4 Million ... The Lustgarten Foundation, the nation,s largest private supporter of pancreatic ... totaling $1.6 million awarded to six leading research centers for ... nation,s deadliest cancers. , , Lustgarten is expected ...
Cached Biology Technology:SyntheMed Receives Frost & Sullivan Health Innovation Award Nomination 2Advanced Life Sciences' Restanza(TM) Shows 100% Survival In Confirmatory Anthrax Study 2Advanced Life Sciences' Restanza(TM) Shows 100% Survival In Confirmatory Anthrax Study 3The Lustgarten Foundation Awards Six Research Centers With Pancreatic Cancer Research Funding 2
... Rabbit polyclonal to Ki67 - Proliferation Marker, ... cell cycle related nuclear protein, expressed by ... active cell cycle (G1, S, G2 and ... (G0) cells. Ki67 antibodies are useful in ...
Rabbit polyclonal to Shigella (HRP) ( Abpromise for all tested applications)....
HLA II DG+DR+DP Monoclonal Antibody, Purified, Unconjugated, Clone: IQU9 This antibody is specific for the monomorphic determinant of the HLA Class II beta chains of the human MHC (28 kDa)....
100 g monoclonal antibody which can immunocapture ~10 g of Complex IV from heart mitochondria. Also included are 2 mg of bovine heart mitochondria for control immunocapture....
Biology Products: